Literature DB >> 29955182

Author Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.

Bjoern Chapuy1,2, Chip Stewart3, Andrew J Dunford3, Jaegil Kim3, Atanas Kamburov3, Robert A Redd4, Mike S Lawrence2,3,5, Margaretha G M Roemer1, Amy J Li6, Marita Ziepert7, Annette M Staiger8,9, Jeremiah A Wala3, Matthew D Ducar10, Ignaty Leshchiner3, Ester Rheinbay3, Amaro Taylor-Weiner3, Caroline A Coughlin1, Julian M Hess3, Chandra S Pedamallu3, Dimitri Livitz3, Daniel Rosebrock3, Mara Rosenberg3, Adam A Tracy3, Heike Horn8, Paul van Hummelen10, Andrew L Feldman11, Brian K Link12, Anne J Novak11, James R Cerhan11, Thomas M Habermann11, Reiner Siebert13, Andreas Rosenwald14, Aaron R Thorner10, Matthew L Meyerson2,3, Todd R Golub2,3, Rameen Beroukhim2,3, Gerald G Wulf15, German Ott9, Scott J Rodig2,16, Stefano Monti6, Donna S Neuberg2,4, Markus Loeffler7, Michael Pfreundschuh17, Lorenz Trümper15, Gad Getz18,19,20, Margaret A Shipp21,22.   

Abstract

In the version of this article originally published, an asterisk was omitted from Fig. 1a. The asterisk has been added to the figure. Additionally, a "NOTCH2" label was erroneously included in Fig. 4a. The label has been removed. The errors have been corrected in the PDF and HTML versions of this article.

Entities:  

Year:  2018        PMID: 29955182     DOI: 10.1038/s41591-018-0097-4

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  13 in total

1.  Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy.

Authors:  Yucai Wang; Umar Farooq; Brian K Link; Melissa C Larson; Rebecca L King; Matthew J Maurer; Cristine Allmer; Mehrdad Hefazi; Carrie A Thompson; Ivana N Micallef; Patrick B Johnston; Thomas M Habermann; Thomas E Witzig; Stephen M Ansell; James R Cerhan; Grzegorz S Nowakowski
Journal:  J Clin Oncol       Date:  2019-06-06       Impact factor: 44.544

2.  Matrix Metallopeptidase 14: A Candidate Prognostic Biomarker for Diffuse Large B-Cell Lymphoma.

Authors:  Chengliang Yin; Junyan Zhang; Ming Shen; Zhenyang Gu; Yan Li; Wanguo Xue; Jinlong Shi; Wenrong Huang
Journal:  Front Oncol       Date:  2020-08-20       Impact factor: 6.244

3.  Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype.

Authors:  Ruben A L de Groen; Ronald van Eijk; Stefan Böhringer; Tom van Wezel; Richard Raghoo; Dina Ruano; Patty M Jansen; Inge Briaire-de Bruijn; Fleur A de Groot; Karin Kleiverda; Liane Te Boome; Valeska Terpstra; Henriette Levenga; Alina Nicolae; Eduardus F M Posthuma; Isabelle Focke-Snieders; Lizan Hardi; Wietske C E den Hartog; Lara H Bohmer; Pancras C W Hogendoorn; Anke van den Berg; Arjan Diepstra; Marcel Nijland; Pieternella J Lugtenburg; Marie José Kersten; Steven T Pals; Hendrik Veelken; Judith V M G Bovée; Arjen H G Cleven; Joost S P Vermaat
Journal:  Blood Adv       Date:  2021-10-12

4.  Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series.

Authors:  Jillian F Wise; Sigve Nakken; Chloé B Steen; Daniel Vodák; Gunhild Trøen; Bjarne Johannessen; Ole Christian Lingjærde; Vera Hilden; Yngvild Nuvin Blaker; Baoyan Bai; Lars Birger Aasheim; Annika Pasanen; Susanne Lorenz; Anita Sveen; Ragnhild A Lothe; Ola Myklebost; Sirpa Leppä; Leonardo A Meza-Zepeda; Klaus Beiske; Michael S Lawrence; Eivind Hovig; June Helen Myklebust; Erlend B Smeland; Harald Holte
Journal:  Blood Adv       Date:  2020-05-12

5.  Abemaciclib, a CDK4/6 inhibitor, exerts preclinical activity against aggressive germinal center-derived B-cell lymphomas.

Authors:  Yuka Tanaka; Shuji Momose; Takayuki Tabayashi; Keisuke Sawada; Takahisa Yamashita; Morihiro Higashi; Morihiko Sagawa; Michihide Tokuhira; Andreas Rosenwald; Masahiro Kizaki; Jun-Ichi Tamaru
Journal:  Cancer Sci       Date:  2020-01-13       Impact factor: 6.716

6.  Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412.

Authors:  Grzegorz S Nowakowski; Fangxin Hong; David W Scott; William R Macon; Rebecca L King; Thomas M Habermann; Nina Wagner-Johnston; Carla Casulo; James L Wade; Gauri G Nagargoje; C M Reynolds; Jonathon B Cohen; Nadia Khan; Jennifer E Amengual; Kristy L Richards; R F Little; John P Leonard; Jonathan W Friedberg; Lale Kostakoglu; Brad S Kahl; Thomas E Witzig
Journal:  J Clin Oncol       Date:  2021-02-08       Impact factor: 50.717

7.  Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways.

Authors:  Hanno M Witte; Axel Künstner; Nadine Hertel; Heinz-Wolfram Bernd; Veronica Bernard; Stephanie Stölting; Hartmut Merz; Nikolas von Bubnoff; Hauke Busch; Alfred C Feller; Niklas Gebauer
Journal:  Blood Adv       Date:  2022-01-25

8.  Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL.

Authors:  Thomas E Witzig; Grzegorz S Nowakowski; Anne J Novak; Keenan T Hartert; Kerstin Wenzl; Jordan E Krull; Michelle Manske; Vivekananda Sarangi; Yan Asmann; Melissa C Larson; Matthew J Maurer; Susan Slager; William R Macon; Rebecca L King; Andrew L Feldman; Anita K Gandhi; Brian K Link; Thomas M Habermann; Zhi-Zhang Yang; Stephen M Ansell; James R Cerhan
Journal:  Leukemia       Date:  2020-03-05       Impact factor: 11.528

9.  Improved personalized survival prediction of patients with diffuse large B-cell Lymphoma using gene expression profiling.

Authors:  Adrián Mosquera Orgueira; José Ángel Díaz Arias; Miguel Cid López; Andrés Peleteiro Raíndo; Beatriz Antelo Rodríguez; Carlos Aliste Santos; Natalia Alonso Vence; Ángeles Bendaña López; Aitor Abuín Blanco; Laura Bao Pérez; Marta Sonia González Pérez; Manuel Mateo Pérez Encinas; Máximo Francisco Fraga Rodríguez; José Luis Bello López
Journal:  BMC Cancer       Date:  2020-10-21       Impact factor: 4.430

10.  Identification of key mutations in central nervous diffuse large B-cell lymphoma (DLBCL) by comprehensive analysis between sequencing and TCGA database.

Authors:  Chunhui Zhou; Yong Cui; Haomin Sun; Fan Yang; Hao Zhao; Luokai Huangfu; Jianning Zhang
Journal:  Transl Cancer Res       Date:  2021-06       Impact factor: 1.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.